Stimulation of γδ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma

Blood - Tập 96 Số 2 - Trang 384-392 - 2000
Volker Kunzmann1, Eva Bauer1, Juliane Feurle1, Hans-Peter Tony Florian Weißinger1, Martin Wilhelm1
1From the Medizinische Poliklinik Wuerzburg, Julius–Maximilians Universität Wuerzburg, Wuerzburg, Germany.

Tóm tắt

AbstractBisphosphonates are well-known inhibitors of osteoclastic bone resorption, but recent clinical reports support the possibility of direct or indirect antitumor effects by these compounds. Because bisphosphonates share structural homologies with recently identified γδ T-cell ligands, we examined the stimulatory capacity of bisphosphonates to γδ T cells and determined whether γδ T-cell stimulation by bisphosphonates could be exploited to generate antiplasma cell activity in multiple myeloma (MM). All tested aminobisphosphonates (alendronate, ibandronate, and pamidronate) induced significant expansion of γδ T cells (Vγ9Vδ2 subset) in peripheral blood mononuclear cell cultures of healthy donors at clinically relevant concentrations (half-maximal activity, 0.9-4 μmol/L). The proliferative response of γδ T cells to aminobisphosphonates was IL-2 dependent, whereas activation of γδ T cells (up-regulation of CD25 and CD69) occurred in the absence of exogenous cytokines. Pamidronate-activated γδ T cells produced cytokines (ie, interferon [IFN]-γ) and exhibited specific cytotoxicity against lymphoma (Daudi) and myeloma cell lines (RPMI 8226, U266). Pamidronate-treated bone marrow (BM) cultures of 24 patients with MM showed significantly reduced plasma cell survival compared with untreated cultures, especially in cultures in which activation of BM-γδ T cells was evident (14 of 24 patients with MM). γδ T-cell depletion from BM cultures completely abrogated the cytoreductive effect on myeloma cells in 2 of 3 tested patients with MM. These results show that aminobisphosphonates stimulating γδ T cells have pronounced effects on the immune system, which might contribute to the antitumor effects of these drugs.

Từ khóa


Tài liệu tham khảo

Berenson, 1996, Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma: Myeloma Aredia Study Group., N Engl J Med., 334, 488, 10.1056/NEJM199602223340802

McCloskey, 1998, A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma: MRC Working Party on Leukaemia in Adults., Br J Haematol., 100, 317, 10.1046/j.1365-2141.1998.00567.x

Rodan, 1996, Bisphosphonates: mechanisms of action., J Clin Invest., 97, 2692, 10.1172/JCI118722

Berenson, 1998, Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events: Myeloma Aredia Study Group., J Clin Oncol., 16, 593, 10.1200/JCO.1998.16.2.593

Dhodapkar, 1998, Antimyeloma activity of pamidronate in vivo., Br J Haematol., 103, 530, 10.1046/j.1365-2141.1998.00976.x

Sasaki, 1995, Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice., Cancer Res., 55, 3551

Massaia, 1993, Rapid generation of antiplasma cell activity in the bone marrow of myeloma patients by CD3-activated T cells., Blood., 82, 1787, 10.1182/blood.V82.6.1787.1787

Peest, 1995, Tumor-directed cytotoxicity in multiple myeloma—the basis for an experimental treatment approach with interleukin 2., Stem Cells., 2, 72

Kwak, 1995, Transfer of myeloma idiotype-specific immunity from an actively immunised marrow donor., Lancet., 345, 1016, 10.1016/S0140-6736(95)90757-2

Haas, 1993, Gamma/delta cells., Annu Rev Immunol., 11, 637, 10.1146/annurev.iy.11.040193.003225

Fisch, 1990, Recognition by human Vγ9/Vδ2 T cells of a GroEL homolog on Daudi Burkitt's lymphoma cells., Science., 250, 1269, 10.1126/science.1978758

Bukowski, 1995, Vγ2Vδ2 TCR-dependent recognition of nonpeptide antigens and Daudi cells analyzed by TCR gene transfer., J Immunol., 154, 998, 10.4049/jimmunol.154.3.998

Tanaka, 1995, Natural and synthetic nonpeptide antigens recognized by human γ/δ T cells., Nature., 375, 155, 10.1038/375155a0

Constant, 1994, Stimulation of human γδ T cells by nonpeptidic mycobacterial ligands., Science., 264, 267, 10.1126/science.8146660

Burk, 1995, Human Vγ9-Vδ2 cells are stimulated in a cross-reactive fashion by a variety of phosphorylated metabolites., Eur J Immunol., 25, 2052, 10.1002/eji.1830250737

Tanaka, 1994, Nonpeptide ligands for human γδ T cells., Proc Natl Acad Sci U S A., 91, 8175, 10.1073/pnas.91.17.8175

De Libero, 1997, Sentinel function of broadly reactive human γδ T cells., Immunol Today., 18, 22, 10.1016/S0167-5699(97)80010-2

Kunzmann, 1999, γ/δ T-cell stimulation by pamidronate [letter]., N Engl J Med., 340, 737, 10.1056/NEJM199903043400914

Tanaka, 1995, Natural and synthetic nonpeptide antigens recognized by human γδ T cells., Nature., 375, 155, 10.1038/375155a0

Leyvraz, 1992, Pharmacokinetics of pamidronate in patients with bone metastases., J Natl Cancer Inst., 84, 788, 10.1093/jnci/84.10.788

Sato, 1991, Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure., J Clin Invest., 88, 2095, 10.1172/JCI115539

Wesch, 1997, Comparative analysis of αβ and γδ T cell activation by Mycobacterium tuberculosis and isopentenyl pyrophosphate., Eur J Immunol., 27, 952, 10.1002/eji.1830270422

Bukowski, 1998, Crucial role of TCR γ chain junctional region in prenyl pyrophosphate antigen recognition by γδ T cells., J Immunol., 161, 286, 10.4049/jimmunol.161.1.286

Luckman, 1998, Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras., J Bone Miner Res., 13, 581, 10.1359/jbmr.1998.13.4.581

Fisher, 1999, Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro., Proc Natl Acad Sci U S A., 96, 133, 10.1073/pnas.96.1.133

Frith, 1997, Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro., J Bone Miner Res., 12, 1358, 10.1359/jbmr.1997.12.9.1358

Sauty, 1996, Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy., Bone., 18, 133, 10.1016/8756-3282(95)00448-3

Thiebaud, 1997, An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates., Calcif Tissue Int., 61, 386, 10.1007/s002239900353

Pecherstorfer, 1998, Effects of the bisphosphonates pamidronate, clodronate and ibandronate on CD69, an early T-lymphocyte activation marker [abstract]., Proc ASCO., 17, 446a

Burk, 1997, Functional inactivation in the whole population of human Vγ9/Vδ2 T lymphocytes induced by a nonpeptidic antagonist., J Exp Med., 185, 91, 10.1084/jem.185.1.91

Wright, 1989, Cytotoxic T lymphocytes specific for self-tumor immunoglobulin express T cell receptor delta chain., J Exp Med., 169, 1557, 10.1084/jem.169.5.1557

Bensussan, 1989, Human CD3 γδ+ activated lymphocytes exhibit killer activity in vitro against autologous leukemic cells., Nouv Rev Fr Hematol., 31, 129

Duval, 1995, Potential antileukemic effect of γδ T cells in acute lymphoblastic leukemia., Leukemia., 9, 863

Lamb, 1996, Increased frequency of TCR γδ+ T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia., J Hematother., 5, 503, 10.1089/scd.1.1996.5.503

Bianchi, 1995, CD3-induced T-cell activation in the bone marrow of myeloma patients: major role of CD4+ cells., Br J Haematol., 90, 625, 10.1111/j.1365-2141.1995.tb05594.x

Burg, 1991, A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma., N Engl J Med., 325, 1078, 10.1056/NEJM199110103251506

Morita, 1991, Functionally distinct subsets of human γ/δ T cells., Eur J Immunol., 21, 2999, 10.1002/eji.1830211215

Portier, 1993, γ-Interferon in multiple myeloma: inhibition of interleukin-6 (IL-6)-dependent myeloma cell growth and downregulation of IL-6-receptor expression in vitro., Blood., 81, 3076, 10.1182/blood.V81.11.3076.3076

Spets, 1998, Fas/APO-1 (CD95)-mediated apoptosis is activated by interferon-γ and interferon-α in interleukin-6 (IL-6)-dependent and IL-6-independent multiple myeloma cell lines., Blood., 92, 2914, 10.1182/blood.V92.8.2914

Shipman, 1997, Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity., Br J Haematol., 98, 665, 10.1046/j.1365-2141.1997.2713086.x

Aparicio, 1998, In vitro cytoreductive effects on multiple myeloma cells induced by bisphosphonates., Leukemia., 12, 220, 10.1038/sj.leu.2400892

Shipman, 1998, The bisphosphonate incadronate (YM175) causes apoptosis of human myeloma cells in vitro by inhibiting the mevalonate pathway., Cancer Res., 58, 5294

Giuliani, 1998, Bisphosphonates inhibit IL-6 production by human osteoblast-like cells., Scand J Rheumatol., 27, 38, 10.1080/030097498441155

Savage, 1996, Pamidronate reduces IL-6 production by bone marrow stroma from multiple myeloma patients [abstract]., Blood., 88, 105a

Thông tin
Thông tin xuất bản

Blood

Tập 96 Số 2

384-392

Thông tin tác giả